Evidence map›Paper›PMID 32416218›Full record

ArticleOsteoarthritis and cartilage2020

Risk scoring for time to end-stage knee osteoarthritis: data from the Osteoarthritis Initiative.

R Dunn, J Greenhouse, D James, D Ohlssen, P Mesenbrink

Abstract read
In one paragraph

Article in Osteoarthritis and cartilage, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

R DunnDepartment of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, 15213, USA. Electronic address: dunnr@cmu.edu.
J GreenhouseDepartment of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, 15213, USA. Electronic address: joel@stat.cmu.edu.
D JamesNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA. Electronic address: davida.james@novartis.com.
D OhlssenNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA. Electronic address: david.ohlssen@novartis.com.
P MesenbrinkNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA. Electronic address: peter.mesenbrink@novartis.com.

Funding

DATA COORDINATING CENTER FOR THE OSTEOARTHRITIS INITIATIVE-264022258N01AR022258 · NIAMS · UNIVERSITY OF CALIFORNIA SYS OFFICE/PRES · 2003 to 2003
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-264022259-264022259N01AR022259 · NIAMS · UNIVERSITY OF MARYLAND AT BALT · PI HOCHBERG, MARC C. · 2002 to 2006
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22260N01AR022260 · NIAMS · UNIVERSITY OF PITTSBURGH · PI KWOH, KENT · 2002 to 2006
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22261N01AR022261 · NIAMS · OHIO STATE UNIVERSITY RESEARCH · PI JACKSON, REBECCA · 2002 to 2006
–
CLINICAL CENTER FOR THE OSTEOARTHRITIS-264022262-264022262N01AR022262 · NIAMS · THE MEMORIAL HOSPITAL · PI ASSAF, ANNLOUISE R. · 2002 to 2006
–
NEW PHARMACOLOGY ASPECTS RELATED TO CARBONIC ANHYDRASER01HL022258 · NHLBI · UNIVERSITY OF FLORIDA · PI MAREN, THOMAS H · 1985 to 1986
–
NHLBI NIH HHS N01 AR022258NIAMS NIH HHS N01 AR022259NIAMS NIH HHS N01 AR022260NIAMS NIH HHS N01 AR022261NIAMS NIH HHS N01 AR022262
6 · The paper itself

Abstract

objectiveThis study constructs a risk score for patients' progression to end-stage knee osteoarthritis (OA) within 4 years.

designThe Osteoarthritis Initiative (OAI) was a longitudinal study of the onset and progression of knee OA. Using a recent definition of end-stage knee OA, we implement interval-censored survival forests to select predictors of this endpoint. We fit an interval-censored Cox model for time to end-stage knee OA, using the selected predictors. The risk score is the Cox model's fitted linear combination of the nine selected baseline structural and symptomatic knee OA variables.

resultsWe fit our models on a training set of 2,701 patients, and we evaluate on an independent test set of 1,436 patients. On the test sample, we observe a concordance index of 0.86 between risk score and time to end-stage, AUC of 0.87 for predicting end-stage within 24, 36, and 48 months, and positive predictive values that increase with the risk score. This risk stratification algorithm could enrich clinical trial patient enrollment. By enrolling test sample patients with scores above a threshold, a trial could have included 91% of test set patients who reach end-stage within 4 years while only enrolling 45% of the test sample.

conclusionUsing statistical methods, we construct and validate an interpretable risk score for time to end-stage knee OA. This score can help disease-modifying OA treatment developers to select candidates with the highest risk of fast-progressing knee OA.

Indexed as

Arthroplasty, Replacement, KneeAgedClinical Decision RulesDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedOsteoarthritis, KneePatient SelectionProportional Hazards ModelsRisk FactorsSeverity of Illness IndexTime FactorsEnd-stage knee osteoarthritisKnee osteoarthritisPredictive modelingRisk score

Identifiers

PMID32416218
PMCPMC7575033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.